JP2024519450A5 - - Google Patents

Info

Publication number
JP2024519450A5
JP2024519450A5 JP2023563935A JP2023563935A JP2024519450A5 JP 2024519450 A5 JP2024519450 A5 JP 2024519450A5 JP 2023563935 A JP2023563935 A JP 2023563935A JP 2023563935 A JP2023563935 A JP 2023563935A JP 2024519450 A5 JP2024519450 A5 JP 2024519450A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
use according
antibody
galectin
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023563935A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024519450A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/027127 external-priority patent/WO2022232641A1/en
Publication of JP2024519450A publication Critical patent/JP2024519450A/ja
Publication of JP2024519450A5 publication Critical patent/JP2024519450A5/ja
Pending legal-status Critical Current

Links

JP2023563935A 2021-04-30 2022-04-29 抗ガレクチン-9抗体及びその治療的使用 Pending JP2024519450A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163182521P 2021-04-30 2021-04-30
US63/182,521 2021-04-30
US202163193357P 2021-05-26 2021-05-26
US63/193,357 2021-05-26
US202263313879P 2022-02-25 2022-02-25
US63/313,879 2022-02-25
PCT/US2022/027127 WO2022232641A1 (en) 2021-04-30 2022-04-29 Anti-galectin-9 antibodies and therapeutic uses thereof

Publications (2)

Publication Number Publication Date
JP2024519450A JP2024519450A (ja) 2024-05-14
JP2024519450A5 true JP2024519450A5 (https=) 2025-05-09

Family

ID=83847350

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023563935A Pending JP2024519450A (ja) 2021-04-30 2022-04-29 抗ガレクチン-9抗体及びその治療的使用

Country Status (8)

Country Link
US (1) US20240190970A1 (https=)
EP (1) EP4329807A4 (https=)
JP (1) JP2024519450A (https=)
AU (1) AU2022266821A1 (https=)
CA (1) CA3217822A1 (https=)
IL (1) IL308014A (https=)
WO (1) WO2022232641A1 (https=)
ZA (1) ZA202309775B (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7581238B2 (ja) * 2019-05-01 2024-11-12 ニューヨーク・ユニバーシティ 抗ガレクチン9抗体およびその使用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY36391A (es) * 2014-11-05 2016-06-01 Flexus Biosciences Inc Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido1), sus métodos de síntesis y composiciones farmacèuticas que las contienen
CA3080120C (en) * 2017-10-27 2023-11-21 New York University Anti-galectin-9 antibodies and uses thereof
AU2020247993A1 (en) * 2019-03-25 2021-11-18 New York University Anti-Galectin-9 antibodies and uses thereof
JP7581238B2 (ja) * 2019-05-01 2024-11-12 ニューヨーク・ユニバーシティ 抗ガレクチン9抗体およびその使用
US20220332832A1 (en) * 2019-08-01 2022-10-20 New York University Combined cancer therapy of anti-galectin-9 antibodies and chemotherapeutics
US20240287195A1 (en) * 2020-10-26 2024-08-29 Puretech Lyt, Inc. Anti-galectin-9 antibodies and uses thereof in the treatment of ocular melanoma
WO2022109299A1 (en) * 2020-11-20 2022-05-27 New York University Anti-galectin-9 antibodies and therapeutic uses thereof
US20240043543A1 (en) * 2020-11-20 2024-02-08 New York University Anti-galectin-9 antibodies and therapeutic uses thereof

Similar Documents

Publication Publication Date Title
JP2021514969A5 (https=)
JP2021513540A5 (https=)
JP2018518454A5 (https=)
JP2020508317A5 (https=)
JP2018519327A5 (https=)
JP2022531408A5 (https=)
JP2017533912A5 (https=)
JP2021510697A5 (https=)
US20180235986A1 (en) Combination therapy for cancer treatment
JP2016516800A5 (https=)
JP2022543780A5 (https=)
JP2022512851A5 (https=)
JPWO2022270524A5 (https=)
RU2017142804A (ru) Лечение пациентов с диагнозом аденокарцинома поджелудочной железы с использованием моноклональных антител к рецептору эпидермального фактора роста (egfr)
JP2024519450A5 (https=)
JP2021511344A5 (https=)
JP2021529777A5 (https=)
Shukla et al. Dostarlimab in the treatment of mismatch repair deficient recurrent or advanced endometrial cancer
CN109806393B (zh) 抗pd-1抗体、培美曲塞和铂类药物联合治疗非小细胞肺癌的用途
JP2024536383A5 (https=)
TW202313694A (zh) 治療癌症以及腫瘤相關之體重減輕及惡病質之方法
JP2022530599A5 (https=)
WO2025103379A1 (zh) 抗b7h3抗体-药物偶联物治疗癌症的方法
WO2021213523A1 (zh) 抗pd-1抗体和抗ctla-4抗体的组合在预防或治疗癌症中的用途
JP2024519449A5 (https=)